Vivek Ramaswamy Calls Axovant Alzheimer's Drug His 'Single Greatest Failure'

Published: Sep 27, 2017

This morning, Vivek Ramaswamy, who began building an empire of six matryoshka-doll biotechnology companies at the age of 29 after a life as a valedictorian, a nationally ranked junior tennis player, a Harvard graduate, and a hedge fund partner, had to face something on a scale he never had before: Failure.

Quite simply, his biggest bet flopped. Axovant Sciences, a company Ramaswamy founded and at one point ran as CEO, said its would-be Alzheimer’s drug, intepirdine, did not help patients in a clinical trial.

Back to news